Diagnosis of Valvular Heart Disease and Myocardial Function

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Medical Imaging and Theranostics".

Deadline for manuscript submissions: 30 September 2024 | Viewed by 7649

Special Issue Editor


E-Mail Website
Guest Editor
1st Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
Interests: echocardiography; speckle tracking; myocardial function; stress echo; 3D echo; valvular heart disease; heart failure; thalassaemia; cardio-oncology; diabetes
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are pleased to invite you to submit your article on any type of valvular heart disease that studies the ventricular or atrial myocardial function.

All the types of primary valvular heart disease affect the myocardial function in a deleterious way. This myocardial impairment is one of the main criteria leading to transcatheter or surgical valvular intervention. In addition, in the recently studied secondary mitral regurgitation and tricuspid regurgitation the ventricular or atrial myocardium is primarily suffering, inducing the functional valvular regurgitation.

Thus, this Special Issue aims to publish articles enlightening the pathophysiology of the ventricular and atrial myocardial damage in case of any type of valvular heart disease, the prognostic value of the myocardial impairment in each case and the clinical consequences of the myocardial deterioration, including the decision-making for an intervention and the myocardial recovery after it.

In this Special Issue, original research articles and reviews are welcome. Research areas may include the following: aortic stenosis, aortic regurgitation, mitral stenosis, mitral regurgitation, tricuspid regurgitation, pulmonary stenosis, pulmonary regurgitation, or mixed or multiple valvular heart disease with a special focus on the myocardial (left/right ventricular or left/right atrial) function by applying any feasible imaging modality.

We look forward to receiving your contributions.

Dr. Vasileios Kamperidis
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • echocardiography
  • speckle tracking
  • 3D echo
  • cardiac mri
  • cardiac perfusion imaging
  • aortic stenosis or regurgitation
  • mitral stenosis or regurgitation
  • tricuspid stenosis or regurgitation
  • pulmonary stenosis or regurgitation
  • transcatheter valvular treatment
  • surgical valvular treatment

Published Papers (4 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Jump to: Other

17 pages, 1570 KiB  
Review
Arrhythmic Mitral Valve Prolapse: A Comprehensive Review
by Yuyan Deng, Jinfeng Liu, Shan Wu, Xiaoming Li, Huimei Yu, Lili Tang, Meng Xie and Chun Zhang
Diagnostics 2023, 13(18), 2868; https://doi.org/10.3390/diagnostics13182868 - 6 Sep 2023
Viewed by 2452
Abstract
Mitral valve prolapse (MVP) is a prevalent cardiac disorder that impacts approximately 2% to 3% of the overall population. While most patients experience a benign clinical course, there is evidence suggesting that a subgroup of MVP patients face an increased risk of sudden [...] Read more.
Mitral valve prolapse (MVP) is a prevalent cardiac disorder that impacts approximately 2% to 3% of the overall population. While most patients experience a benign clinical course, there is evidence suggesting that a subgroup of MVP patients face an increased risk of sudden cardiac death (SCD). Although a conclusive causal link between MVP and SCD remains to be firmly established, various factors have been associated with arrhythmic mitral valve prolapse (AMVP). This study aims to provide a comprehensive review encompassing the historical background, epidemiology, pathology, clinical manifestations, electrocardiogram (ECG) findings, and treatment of AMVP patients. A key focus is on utilizing multimodal imaging techniques to accurately diagnose AMVP and to highlight the role of mitral annular disjunction (MAD) in AMVP. Full article
(This article belongs to the Special Issue Diagnosis of Valvular Heart Disease and Myocardial Function)
Show Figures

Figure 1

11 pages, 236 KiB  
Review
Right Ventricle and Radiotherapy: More Questions than Answers
by Marijana Tadic, Johannes Kersten, Dominik Buckert, Wolfgang Rottbauer and Cesare Cuspidi
Diagnostics 2023, 13(1), 164; https://doi.org/10.3390/diagnostics13010164 - 3 Jan 2023
Cited by 1 | Viewed by 1310
Abstract
The injury of the left ventricle (LV) during anticancer therapy has long been recognized, and guidelines recommend a specific set of parameters for determination of LV impairment. The influence of anticancer therapy on the right ventricle (RV) has been insufficiently investigated, and there [...] Read more.
The injury of the left ventricle (LV) during anticancer therapy has long been recognized, and guidelines recommend a specific set of parameters for determination of LV impairment. The influence of anticancer therapy on the right ventricle (RV) has been insufficiently investigated, and there are only a few studies that have considered the effect of radiotherapy on RV remodeling. On the other hand, large number of patients with different types of cancers located in the chest are treated with radiotherapy, and the negative clinical effects of this treatment such as accelerated coronary artery disease, valve degeneration and heart failure have been documented. The anatomical position of the RV, which is in the front of the chest, is responsible for its large exposure during radiation treatment, particularly in patients with left-sided breast and lung cancers and mediastinal cancers (hematological malignancies, esophagus cancers, thymomas, etc.). For the same reason, but also due to its anatomical complexity, the RV remains under-investigated during echocardiographic examination, which remains the cornerstone of cardiac imaging in everyday practice. In the last decade many new echocardiographic imaging techniques that enable better evaluation of RV structure, function and mechanics appeared, and they have been used in detection of early and late signs of RV injuries in oncological patients. These investigations are related to some important restrictions that include limited numbers of patients, used parameters and imaging techniques. Many questions about the potential impact of these changes and possible predictions of adverse events remain to be evaluated in future large longitudinal studies. The current body of evidence indicates an important role of radiotherapy in RV remodeling, and therefore, the aim of this review is to summarize currently available data regarding RV changes in patients with various oncological conditions and help clinicians in the assessment of possible cardiac damage. Full article
(This article belongs to the Special Issue Diagnosis of Valvular Heart Disease and Myocardial Function)

Other

Jump to: Review

10 pages, 1636 KiB  
Study Protocol
Clinical Value of Novel Echocardiographic Biomarkers Assessing Myocardial Work in Acute Heart Failure—Rationale and Design of the “Beyond Myo-HF Study”
by Vasileios Anastasiou, Stylianos Daios, Dimitrios V. Moysidis, Maria-Anna Bazmpani, Thomas Zegkos, Theodoros Karamitsos, Kali Makedou, Christos Savopoulos, Georgios Efthimiadis, Antonios Ziakas and Vasileios Kamperidis
Diagnostics 2023, 13(6), 1191; https://doi.org/10.3390/diagnostics13061191 - 21 Mar 2023
Viewed by 1076
Abstract
Background. Despite ongoing treatment advancements in chronic heart failure (HF), mortality and readmission rates remain high for patients hospitalized for decompensated acute HF. These patients represent a distinct HF group, which requires emergent echocardiographic evaluation in an attempt to provide optimal and individualized [...] Read more.
Background. Despite ongoing treatment advancements in chronic heart failure (HF), mortality and readmission rates remain high for patients hospitalized for decompensated acute HF. These patients represent a distinct HF group, which requires emergent echocardiographic evaluation in an attempt to provide optimal and individualized acute care. The role of serial advanced echocardiographic assessment in acute HF for risk stratification and treatment guidance has not been thoroughly explored. Methods. The “Beyond Myo-HF Study” is a prospective, non-interventional cohort trial designed to enroll acutely admitted patients with symptoms and/or signs of HF. The aim of this study is to investigate whether intrahospital changes of conventional and novel echocardiographic indices of myocardial function and congestion-related markers can predict early mortality, late mortality, and HF rehospitalization. As per the protocol, all patients undergo a pair of state-of-the-art echocardiographic assessments, with a rigorous protocol including speckle tracking analysis of all cardiac chambers and myocardial work analysis for the left and right ventricle, upon admission and pre-discharge. Their laboratory profile is captured at those two time-points, and their therapeutic management is recorded. Patients will be followed-up for a median period of 12 months after enrollment. Conclusions. The “Beyond Myo-HF” study is an ongoing, prospective trial aspiring to provide deep insight into the pathophysiology of acute HF, to enlighten the reverse cardiac functional and anatomical remodeling during hospitalization, and to recognize echocardiographic patterns capable of predicting adverse outcomes during and post decompensation of acute HF. Full article
(This article belongs to the Special Issue Diagnosis of Valvular Heart Disease and Myocardial Function)
Show Figures

Figure 1

7 pages, 2508 KiB  
Case Report
The Role of Echocardiography in the Diagnosis of Cardiac Involvement in a Rare Systemic Condition: The Carcinoid Heart Disease: A Case Report and Review of Literature
by Adela Șerban, Alexandra Dădârlat-Pop, Raluca Tomoaia, Claudia Hagiu, Dan Axente, Valer Donca and Mihai Suceveanu
Diagnostics 2022, 12(12), 2929; https://doi.org/10.3390/diagnostics12122929 - 24 Nov 2022
Viewed by 1968
Abstract
Carcinoid heart disease is a rare presentation of the carcinoid syndrome, which is caused by excessive tumoral hormone production and the abundant release of vasoactive substances with systemic expressions. A 62-year-old woman presented with flushing, diarrhea, weight loss, and right-sided heart failure symptoms. [...] Read more.
Carcinoid heart disease is a rare presentation of the carcinoid syndrome, which is caused by excessive tumoral hormone production and the abundant release of vasoactive substances with systemic expressions. A 62-year-old woman presented with flushing, diarrhea, weight loss, and right-sided heart failure symptoms. Specific carcinoid heart disease features were identified using transthoracic and transesophageal echocardiography at the tricuspid and pulmonic valves. Biomarkers, 99mTc-Tektrotyd scintigraphy, SPECT-CT, and a biopsy later confirmed the diagnosis, and the patient began treatment for the underlying condition. Full article
(This article belongs to the Special Issue Diagnosis of Valvular Heart Disease and Myocardial Function)
Show Figures

Figure 1

Back to TopTop